NTRC 3531-0 / Crossfire Oncology - LARVOL DELTA

The dual face of microglia (M1/M2) as a potential target in the protective effect of nutraceuticals against neurodegenerative diseases. (PubMed, Front Aging) - "Asarone, galangin, baicalein, and a-mangostin reduced oxidative stress and pro-inflammatory cytokines, such as interleukin (IL)-1, IL-6, and tumor necrosis factor-alpha in M1-activated microglia in Parkinson's disease...Additionally, emodin, esters of gallic and rosmarinic acids, Agathisflavone, and sinomenine offered promising multiple sclerosis treatments. This review highlights the therapeutic potential of using nutraceuticals to treat neurodegenerative diseases involving microglial-related pathways."

Journal • Review • Alzheimer's Disease • CNS Disorders • Huntington's Disease • Immunology • Movement Disorders • Multiple Sclerosis • Oncology • Parkinson's Disease • IL6 • TNFA

Search for potential inhibitors of the human Tryptophan 2,3-dioxygenase (hTDO) protein using pharmacophore-based virtual screening, molecular docking, and molecular dynamics simulation studies (ACS-Fall 2023) - "Alzheimer's disease, Parkinson's and multiple sclerosis are among the most common neurodegenerative disorders around the world...The ligands that meet the established criteria will be subjected to molecular docking studies and molecular dynamics simulation. The selected compounds are expected to have a behavior similar to the hTDO inhibitors, LM10 and NTRC 3531-0, previously reported."

Alzheimer's Disease • CNS Disorders • Movement Disorders • Multiple Sclerosis • Parkinson's Disease • TDO2

A systematic review of the prognostic value of motor abnormalities on clinical outcome in psychosis. (PubMed, Neurosci Biobehav Rev) - "We found increased levels of MAs, in particular NSS, parkinsonism, and dyskinesia, were related to deteriorating symptomatic and poor functional outcome over time. Collectively, the findings emphasize the clinical, prognostic and scientific relevance of MA assessment and detection in individuals with or at risk of psychosis. In the future, instrumental measures of MA are expected to further augment detection, early intervention and treatment strategies in psychosis."

Clinical • Clinical data • Journal • Review • CNS Disorders • Movement Disorders • Parkinson's Disease • Psychiatry • Schizophrenia

Pharmacological validation of TDO as a target for Parkinson's disease. (PubMed, FEBS J) - "Consistent with this, mice treated with TDO inhibitor showed decreased expression of rotenone-induced glial fibrillary acidic protein, which is a marker of enteric glial cells, and decreased α-synuclein accumulation in the enteric plexus. Our data support TDO inhibition as a potential therapeutic strategy to decrease motor, cognitive and gastrointestinal symptoms in Parkinson's disease."

IO biomarker • Journal • CNS Disorders • Cognitive Disorders • Gastrointestinal Disorder • Immunology • Inflammation • Movement Disorders • Parkinson's Disease • GFAP • IDO1

[VIRTUAL] PHARMACOLOGICAL VALIDATION OF TRYPTOPHAN 2,3-DIOXYGENASE (TDO) AS A TARGET FOR PARKINSON’S DISEASE (AAT-ADPD 2020) - "In addition, both inhibitors reduced gross colonic inflammation, glial cells activation and enteric neuronal α-synuclein accumulation in PD mice. Conclusions Taken together, this study indicates that modulation of the kynurenine pathway through inhibition of TDO with small molecular compounds might be a potential therapeutic strategy for PD."